Table 1. Baseline characteristics of the study group.
| Characteristic | HeartMate II patients, N=16 |
|---|---|
| Male | 15 (93.8) |
| Female | 1 (6.2) |
| Average age (years) | 52.13±12.99 |
| Average body mass index (kg/m2) | 27.52±4.45 |
| Diagnoses | |
| Dilated cardiomyopathy | 9 (56.3) |
| Ischemic cardiomyopathy | 7 (43.8) |
| NYHA profile | |
| IV | 6 (37.5) |
| III | 8 (50.0) |
| II | 2 (12.5) |
| INTERMACS profile | |
| I | 1 (6.3) |
| II | 0 (0.0) |
| III | 15 (93.8) |
| IV | 0 (0.0) |
| Atrial fibrillation pre-OP | 0 (0.0) |
| Dialysis pre-OP | 1 (6.3) |
| Dialysis post-OP | 4 (25.0) |
| ECMO pre-OP | 1 (6.3) |
| ECMO post-OP | 3 (18.8) |
| Mean days on support | 604.94±550.39 |
| Mean days until LVAD exchange | 261.44±363.03 |
| Stay | |
| Average in-hospital stay after LVAD implantation (days) | 35.73±50.78 |
| Average ICU stay (days) | 4.14±6.20 |
| Average erythrocyte concentrate until discharge | 7.67±5.35 |
| Status | |
| Cardiac transplantation | 2 (12.5) |
| LVAD explantation due to recovery | 1 (6.3) |
| Death after LVAD implantation | 8 (50.0) |
Data are shown as number (%) or mean ± SD. ECMO, extracorporeal membrane oxygenation; LVAD, left ventricular assist device.